Literature DB >> 20015097

Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.

Jennifer A Woyach1, Nyla A Heerema, John Zhao, Andrew McFaddin, Amy Stark, Thomas S Lin, Leslie A Andritsos, Kristie A Blum, Joseph M Flynn, Jeffrey A Jones, John C Byrd.   

Abstract

Interphase cytogenetics are commonly used to identify clonal abnormalities in chronic lymphocytic leukemia (CLL) patients but fail to identify recurrent translocations that ultimately can direct more focused molecular characterization. Given the importance of del(17p13.1) in CLL outcome, we performed an extensive review of 1213 patients undergoing metaphase cytogenetics at our institution and identified 16 (1.3%) with a recurrent unbalanced translocation between the p arms of chromosomes 17 and 18 that results in a dicentric chromosome with loss of much of 17p and 18p. The dic(17;18)(p11.2;p11.2) was associated with a complex (three or more unrelated cytogenetic abnormalities) karyotype in 12 patients (75%) at the time that the abnormality was first identified, and eventually associated with a complex karyotype in 94% of patients. IGHV mutational analysis was un-mutated in 88% of cases where evaluation was possible. Except for one patient who was diagnosed with CLL incidentally during a workup for metastatic tonsillar cancer, all patients identified with dic(17;18)(p11.2;p11.2) met criteria for disease treatment, with a median time from diagnosis to first treatment of 15 months. Our data demonstrate that dic(17;18)(p11.2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression. Future efforts to identify genes disrupted by this translocation are warranted and ongoing.

Entities:  

Mesh:

Year:  2009        PMID: 20015097      PMCID: PMC2902554          DOI: 10.1111/j.1365-2141.2009.08007.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

1.  Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia.

Authors:  K Maloum; F Davi; H Merle-Béral; O Pritsch; C Magnac; F Vuillier; G Dighiero; X Troussard; F F Mauro; J Bénichou
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

2.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

3.  Cytogenetic, FISH, and molecular studies in a case of B-cell chronic lymphocytic leukemia with karyotypic evolution.

Authors:  Christian Chena; Roxana Cerretini; María Fernanda Noriega; Marina Narbaitz; Mariano Scolnik; María Fernanda Palacios; Daniela Neme; Salvador Bruno; Irma Slavutsky
Journal:  Eur J Haematol       Date:  2002 Nov-Dec       Impact factor: 2.997

4.  More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia.

Authors:  Ritva Karhu; Gerard Tobin; Ulf Thunberg; Leena Vilpo; Christer Sundström; Sakari Knuutila; Richard Rosenquist; Juhani Vilpo
Journal:  Genes Chromosomes Cancer       Date:  2003-08       Impact factor: 5.006

5.  Genome architecture catalyzes nonrecurrent chromosomal rearrangements.

Authors:  Paweł Stankiewicz; Christine J Shaw; Jason D Dapper; Keiko Wakui; Lisa G Shaffer; Marjorie Withers; Leah Elizondo; Sung-Sup Park; James R Lupski
Journal:  Am J Hum Genet       Date:  2003-03-20       Impact factor: 11.025

6.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

Authors:  David G Oscier; Anne C Gardiner; Sarah J Mould; Sharron Glide; Zadie A Davis; Rachel E Ibbotson; Martin M Corcoran; Robert M Chapman; Peter W Thomas; J Adrian Copplestone; Jenny A Orchard; Terry J Hamblin
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

7.  V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

Authors:  Alexander Kröber; Till Seiler; Axel Benner; Lars Bullinger; Elsbeth Brückle; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

9.  Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia.

Authors:  Yuri Vasconcelos; Frédéric Davi; Vincent Levy; Pablo Oppezzo; Christian Magnac; Ariane Michel; Mihoko Yamamoto; Otto Pritsch; Hélène Merle-Béral; Karim Maloum; Florence Ajchenbaum-Cymbalista; Guillaume Dighiero
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

10.  Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine.

Authors:  E Van Den Neste; V Robin; J Francart; A Hagemeijer; M Stul; P Vandenberghe; A Delannoy; A Sonet; V Deneys; S Costantini; A Ferrant; A Robert; L Michaux
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

View more
  6 in total

1.  Jumping translocations, a novel finding in chronic lymphocytic leukaemia.

Authors:  Cecelia R Miller; Deborah Stephens; Amy S Ruppert; Frederick Racke; Andrew McFaddin; Heather Breidenbach; Huey-Jen Lin; Kathy Waller; Tammy Bannerman; Jeffrey A Jones; Jennifer A Woyach; Leslie A Andritsos; Kami Maddocks; Weiqiang Zhao; Gerard Lozanski; Joseph M Flynn; Michael Grever; John C Byrd; Nyla A Heerema
Journal:  Br J Haematol       Date:  2015-04-19       Impact factor: 6.998

2.  Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.

Authors:  Jane Houldsworth; Asha Guttapalli; Venkata Thodima; Xiao Jie Yan; Geetu Mendiratta; Tania Zielonka; Gouri Nanjangud; Weiyi Chen; Sujata Patil; Anthony Mato; Jennifer R Brown; Kanti Rai; Nicholas Chiorazzi; R S K Chaganti
Journal:  Leuk Lymphoma       Date:  2013-11-12

3.  A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL.

Authors:  Jennifer A Woyach; Farrukh Awan; Ian W Flinn; Jesus G Berdeja; Elizabeth Wiley; Sharmeen Mansoor; Ying Huang; Gerard Lozanski; Paul A Foster; John C Byrd
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

4.  Co-occurrence of JAK2 V617F-mutated essential thrombocythemia and chronic lymphocytic leukemia harboring der(8;17)(q10;q10).

Authors:  Masahiro Manabe; Nao Tanizawa; Satoru Nanno; Yuuji Hagiwara; Reiko Asada; Ki-Ryang Koh
Journal:  Cancer Rep (Hoboken)       Date:  2022-06-17

5.  A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Faten Moassass; Moneeb Abdullah Kassem Othman
Journal:  Mol Cytogenet       Date:  2012-08-20       Impact factor: 2.009

Review 6.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.